{
  "id": 5598167,
  "title": "MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?",
  "url": "https://urgent.news/2026/09/04/mimrylo-approval-triggered-275m-payments-for-protagonist-ptgx-are",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-04T16:14:22.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/mimrylo-approval-triggered-275m-payments-161422910.html"
  },
  "original_language": "en",
  "account": "The U.S. Food and Drug Administration's approval of MIMRYLO, a treatment for erythrocytosis in adults with polycythemia vera, has led to $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). This sum includes a $200 million opt-out fee and a $75 million approval milestone. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) decided to opt for royalties instead of the original 50:50 profit-and-loss arrangement with Takeda Pharmaceutical Company Limited (NYSE:TAK).",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}